DPP-4 inhibitors and GLP-1RAs:cardiovascular safety and benefits

作     者：Michael Razavi Ying-Ying Wei Xiao-Quan Rao Ji-Xin Zhong Michael Razavi;Ying-Ying Wei;Xiao-Quan Rao;Ji-Xin Zhong

作者机构：Tulane University School of MedicineNew OrleansLA 70112USA Department of Rheumatology and ImmunologyTongji HospitalTongji Medical College of Huazhong University of Science and Technology1095 Jiefang AveWuhan 430032China Department of Cardiovascular MedicineTongji HospitalTongji Medical College of Huazhong University of Science and Technology1095 Jiefang AveWuhan 430032China Institute of Allergy and Clinical ImmunologyTongji HospitalTongji Medical College of Huazhong University of Science and TechnologyWuhan 430032China 

出 版 物：《Military Medical Research》 (军事医学研究（英文版）)

年 卷 期：2023年第10卷第2期

页      面：227-241页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(81974254 31870906 and 82170470)。 

主　　题：Glucagon-like peptide-1 receptor agonists Dipeptidyl peptidase-4 inhibitors Type 2 diabetes mellitus Cardiovascular outcome 

摘      要：Glucagon-like peptide-1 receptor agonists(GLP-1RAs)and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus(T2DM).Both anti-diabetic treatments function by playing key modulatory roles in the incretin system.Though these drugs have been deemed effective in treating T2DM,the Food and Drug Administration(FDA)and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints.As a result,since 2008,the FDA has required all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety.The present review article strives to assess the safety and benefits of incretin-based therapy,a new class of antidiabetic drug,on the health of patient cardiovascular systems.In the process,this review will also provide a physiological overview of the incretin system and how key components function in T2DM.